#ESCCongress – Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation – New England Journal of Medicine (free)

Commentaries: Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention – RE-DUAL PCI – American College of Cardiology, Latest in Cardiology (free) Dual Antithrombotic Therapy Is Safe for Patients with AF and a New Stent – Physician’s First Watch (free) AND When two is better than three: Dual antithrombotic therapy cuts bleeding risk – Brigham and Women’s Hospital, via ScienceDaily (free)

“In summary, several lines of evidence now suggest that it is safe to treat atrial fibrillation patients who undergo coronary revascularization with anticoagulation (warfarin studied in WOEST, rivaroxaban studied in PIONEER AF-PCI, dabigatran studied in RE-DUAL PCI) and clopidogrel monotherapy” (from American College of Cardiology, Latest in Cardiology).